Oculistica

Dottoressa

Maria Oliva Grassi

Prenota Online

Informazioni personali

Laureata e specializzata in Oftalmologia presso l’Università degli Studi di Bari, ha conseguito il titolo di Dottore di Ricerca in Neuroscienze ed abilitazione a Professore Associato.

Svolge la sua attività clinica, chirurgica e di ricerca presso il Policlinico di Bari dove si dedica prevalentemente alle patologie retiniche (OCT, Angio-OCT, Fluorangiografia), alla chirurgia della cataratta e all’attività di pronto soccorso oculistico.

In particolare, si occupa del Centro di Terapie Intravitreali con Arco Sterile (primo centro di eccellenza in Italia), dove i pazienti con maculopatia vengono sottoposti ad iniezioni intravitreali.

Nella sua decennale esperienza presso il proprio Studio Medico Grassi sito in Gioia del Colle, si è specializzata nella gestione dei vizi rifrattivi (miopia, ipermetropia, astigmatismo, presbiopia) specie nei bambini piccoli ed adolescenti.

Formazione accademica

Certificati e riconoscimenti

Formazione e Titoli di Studio

2025 – Abilitazione Scientifica Nazionale per Professore Associato (Conseguita il 07/10/2025, valida fino al 07/10/2037)

2023 – Dottorato di Ricerca in Neuroscienze presso il Dipartimento di Oftalmologia, Università degli Studi di Bari “Aldo Moro” (04/05/2023)

2021 – Master breve STARBIS (Statistica, ricerca biomedica e salute) presso il Dipartimento di Economia e Finanza, Università degli Studi di Bari “Aldo Moro”

2016 – Specializzazione in Oftalmologia presso il Dipartimento di Oftalmologia, Università degli Studi di Bari “Aldo Moro” (18/03/2016, Votazione: 70/70 con lode)

2009 – Laurea in Medicina e Chirurgia presso la Facoltà di Medicina, Università degli Studi di Bari “Aldo Moro” (31/03/2009, Votazione: 110/110 con lode)

2002 – Diploma di Maturità (04/07/2002, Votazione: 100/100)

Corsi di Aggiornamento e Riconoscimenti

2020 – Writing in the Sciences – Stanford University (Coursera, Maggio 2020)

2020 – Advanced English: Scientific Writing – Università degli Studi di Genova (Eduopen, 08/04/2020)

2019 – Spectralis Multimodality Imaging Course (Bari, 26/06/2019)

2019 – Corso ESASO (Module M0319 on Medical Retina) (Roma, 25 Febbraio – 1 Marzo 2019)

2018 – Corso ESASO: “Trattamento dell’edema maculare diabetico” (Lugano, 20-21/04/2018)

2017 – Premio “Galleria Immagini”, conferito dal Dott. Joseph Carroll in occasione del V Congresso Internazionale di Angiografia OCT, OCT “en face” e progressi nell’OCT (Roma, 14-15 Dicembre 2017)

2016 – Corso base di Angiografia OCT (Roma, 17/06/2016)

2015 – Corso teorico-pratico di Eco-Oftalmologia ed OCT (Torino – Salerno – Chieti, 2015)

Feedback dei pazienti

Chiarezza nella comunicazione
0%
Fiducia del paziente
0%
Valutazione media
0%

Pubblicazioni Scientifiche

1. Factors influencing the number of anti-VEGF injections in myopic choroidal neovascularization: A Multicenter Study.
Retina. 2025.
2. AI-Assisted OCT Clinical Phenotypes of Diabetic Macular Edema: A Large Cohort Clustering Study.
J Clin Med. 2025.
3. Incidence and reasons for discontinuation of anti-VEGF treatment in neovascular age-related macular degeneration.
Br J Ophthalmol. 2025 Apr.
4. Impact of diabetes and diabetic retinopathy on neovascular exudative age-related macular degeneration.
Acta Ophthalmol. 2025 Apr.
5. Real-world Intravitreal Aflibercept 2 mg Treatment of Macular Oedema Secondary to Retinal Vein Occlusion in Italy: 24-month Results from the AURIGA Observational Study.
Ophthalmologica. 2025 Apr.
6. Intravitreal Dexamethasone Implant in Vitreoretinal Surgery: An Overview of the Literature.
Graefes Arch Clin Exp Ophthalmol. 2025 Mar.
7. Twelve-Month Outcomes and Optical Coherence Tomography (OCT) Biomarkers After Intravitreal Dexamethasone Implantation in Pseudophakic Eyes with Post-Vitrectomy Cystoid Macular Edema (CME)-Refractory to Medical Therapy.
Diagnostics (Basel). 2025 Jan.
8. Topographical Quantification of Hyper-Reflective Foci May Predict the Development of Macular Atrophy in Patients With Neovascular Age-Related Macular Degeneration.
Invest Ophthalmol Vis Sci. 2024 Dec.
9. Micropulse Laser versus Eplerenone for Chronic Central Serous Chorioretinopathy: A 12-Month Comparison.
Ophthalmol Ther. 2024 Dec.
10. Multifocal Electroretinography Changes in Patients with Late-Stage Age-Related Macular Degeneration (AMD) After Smaller-Incision New-Generation Implantable Miniature Telescope (SING IMT): A Case Series.
J Pers Med. 2024 Nov.
11. Regression of the Flow Signal from the Neovascular Network in AMD Neovascular Membranes Treated with Faricimab.
Diagnostics (Basel). 2024 Nov.
12. Multimodal imaging in diabetic retinopathy and macular edema: An update about biomarkers.
Surv Ophthalmol. 2024 Nov-Dec.
13. Liposomal Ozonated Oil Ensures a Further Reduction in the Microbial Load Before Intravitreal Injection: the “OPERA” Study.
Ophthalmol Ther. 2024 Oct.
14. Long-term visual outcomes and optical coherence tomography biomarkers in eyes with macular edema secondary to retinal vein occlusion following anti-vascular endothelial growth factor therapy.
Retina. 2024 Sep.
15. Long-Term Impact of Diabetic Retinopathy on Response to Anti-VEGF Treatment in Neovascular AMD.
Invest Ophthalmol Vis Sci. 2024 Aug.
16. Immediate effect of anti-VEGF injections on optic nerve head: Correlation between intraocular pressure and anatomical peripapillary changes.
Eur J Ophthalmol. 2024 Jul.
17. Comparative Study on Anti-VEGF in Wet Age-Related Macular Degeneration in the Setting Based on Lean Methodology from the Bari Intravitreal Injection Registry (BIVIR).
Ophthalmol Ther. 2024 Jun.
18. Neurovascular retinal impairment in early-treated adults with phenylketonuria.
Front Neurol. 2024 Jun.
19. Enhancing Diabetic Macular Edema Treatment Outcomes: Exploring the ESASO Classification and Structural OCT Biomarkers.
Ophthalmol Ther. 2024 May.
20. Validation of Esaso Classification of Diabetic Maculopathy.
Eur J Ophthalmol. 2024 Mar.
21. Choroidal remodeling following different anti-VEGF therapies in neovascular AMD.
Sci Rep. 2024 Jan.
22. Optical coherence tomography biomarkers indicating visual enhancement in diabetic macular edema resolved through anti-VEGF therapy: OCT biomarkers in resolved DME.
Photodiagnosis Photodyn Ther. 2024.
23. Choriocapillaris Reperfusion in Resolved Chronic Central Serous Chorioretinopathy Treated with Eplerenone: Long Term Effects on the Fellow Eye.
Ophthalmol Ther. 2023 Dec.
24. Short-term peripapillary structural and vascular changes following anti-VEGF vs. Dexamethasone intravitreal therapy in patients with DME.
Eur J Ophthalmol. 2023 Nov.
25. The Impact of Diabetic Retinopathy on the Choriocapillaris in Neovascular AMD.
Invest Ophthalmol Vis Sci. 2023 Nov.
26. Effects of diabetic retinopathy on longitudinal morphological changes in AMD-associated type 1 macular neovascularization.
Sci Rep. 2023 Sep.
27. Continuous Eplerenone Treatment in Chronic Central Serous Chorioretinopathy: Long-Term Results from a Pilot Study.
Clin Ophthalmol. 2023 Jul.
28. Severe visual loss during anti-VEGF intravitreal injections in neovascular age-related macular degeneration: Timing, Prognosis and Optical Coherence Tomography Findings.
Retina. 2023.
29. Anterior chamber bleeding due to intravitreal dexamethasone implant sclerotomy without vitreous hemorrhage.
Eur J Ophthalmol. 2023.
30. Topographical Analysis of the Choriocapillaris Reperfusion After Loading Anti-VEGF Therapy in Neovascular AMD.
Transl Vis Sci Technol. 2022 Sep 1;11(9):18.
31. Short-Term Morphofunctional Changes in Previously Treated Neovascular AMD Eyes Switched to Brolucizumab.
J Clin Med. 2022 Sep 21;11(19):5517.
32. Mid-term safety and effectiveness of intravitreal dexamethasone implant to treat persistent cystoid macular edema in vitrectomized eyes for bacterial endophthalmitis.
Graefes Arch Clin Exp Ophthalmol. 2022.
33. Ciliochoroidal effusion syndrome associated with mebendazole systemic treatment.
Can J Ophthalmol. 2022.
34. Diabetic Macular Edema and Cataract Surgery: Phacoemulsification Combined With Dexamethasone Intravitreal Implant Compared With Standard Phacoemulsification.
Retina. 2021.
35. Effect of COVID-19-related lockdown on ophthalmic practice in Italy: A report from 39 institutional centers. Eyecare in Italy during COVID-19 pandemic (EICO) study group.
Eur J Ophthalmol. 2021.
36. Implementation of Lean healthcare methodology in designing an intravitreal injection center: First Italian experience.
Int Ophthalmol. 2020.
37. Intravitreal Injections in Arc Sterile Setting: safety profile after more than 10,000 treatments.
J Ophthalmol. 2020.
38. Optical coherence tomography angiography in diabetic patients without diabetic retinopathy.
Eur J Ophthalmol. 2019.
39. OCT Angiography in Acute Posterior Multifocal Placoid Pigment Epitheliopathy.
Ophthalmic Surg Laser Imaging Retina. 2019.
40. One-year outcomes of 27-gauge versus 25-gauge pars plana vitrectomy for uncomplicated rhegmatogenous retinal detachment repair.
Int J Retina Vitreous. 2019.
41. Choroidal neovascularization due to choroidal osteoma treated with anti-VEGF therapy: an optical coherence tomography angiography study.
Eur J Ophthalmol. 2018.
42. Combined Phacoemulsification and Intravitreal Dexamethasone Implant (Ozurdex®) in Diabetic Patients with coexisting Cataract and Diabetic Macular Edema.
J Ophthalmol. 2017.